Home » Newsletters » BioWorld Science

BioWorld Science

April 20, 2016

View Archived Issues

GeoVax gives update on its Zika vaccine program

Enterome signs exclusive worldwide license agreement with Vertex for IBD therapeutical agents

CytoDyn reports complete viral load suppression in ongoing PRO-140 monotherapy extension study

Protein Sciences, Sinergium Biotech and the Mundo Sano collaborate on Zika vaccine

Treatment completed in BioSight's phase I/IIa trial of Astarabine

Sucampo to discontinue development of cobiprostone in PPI-refractory NERD/sGERD

Bristol-Myers Squibb discloses kallikrein B inhibitors

Bristol-Myers Squibb reports AP2-associated protein kinase 1 inhibitors

Merck & Co. introduces IRAK-4 inhibitors

Xuzhou Yes Biotechnology divulges TNF-alpha-binding antibodies

Lpath completes phase I study of Lpathomab

Preclinical development of Trk-A inhibitor GVK-904

First in-human trial evaluating MVT-5873 in CA19-9-positive malignancies

Assembly Biosciences discloses novel CpAM candidate

BARDA awards contract to Basilea for phase III development of ceftobiprole

Arbutus Biopharma presents novel small-molecule inhibitor of HBV capsid assembly

Astex and Genentech collaborate to study guadecitabine with atezolizumab in AML

Dyanavel XR launched in the U.S. for the treatment of children with ADHD

Elbasvir and grazoprevir granted priority review in Japan

Tecfidera filed for approval for the prevention of multiple sclerosis in Japan

MedImmune gains IND approval to begin phase I trial of anti-ILT7 antibody

ITPase activity linked to tolerability of combination antiretroviral regimens for HIV infection

Arno Therapeutics focuses onapristone development on mCRPC

YKP-3089 reduces frequency of partial-onset seizures and achieves seizure freedom as adjunct therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...